Journal ArticleOPEN ACCESS

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

Cancer Science (2018) 109(1) 174-181
DOI: 10.1111/cas.13427
82Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P

Author supplied keywords

Cite

CITATION STYLE

APA

Fazio, N., Buzzoni, R., Delle Fave, G., Tesselaar, M. E., Wolin, E., Van Cutsem, E., … Yao, J. C. (2018). Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Science, 109(1), 174–181. https://doi.org/10.1111/cas.13427

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free